Devita, Hellman, and Rosenberg's Cancer

LWBK1006-18 LWW-Govindan-Review November 24, 2011 11:24

CHAPTER 18 CANCER OF

THE LUNG

SAIAMA N. WAQAR

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 18.1. Which of the following statements is INCORRECT regarding epidermal

growth factor receptor (EGFR) mutations in lung cancer?

A. EGFR mutations are observed in approximately 80% of non-small

cell lung cancers (NSCLCs).

B. Mutations which predict response to EGFR–tyrosine kinase

inhibitors include exon 19 deletion and a point mutation (L858R)

in exon 21.

C. The L858R mutation renders EGFR constitutively active.

D. EGFR mutations are seen more frequently in tumors from patients

who are nonsmokers, in women, and in Asian populations.

Question 18.2. Which of the following statements is/are CORRECT regarding molecular

abnormalities observed in lung cancer?

A. Chromosomal translocations have not been seen in NSCLC.

B. C-Kit expression is seen in most NSCLCs.

C. Chromosome 3p allele loss is one the most common events in lung

cancer pathogenesis.

D. All of the above.

Question 18.3. A 55-year-old man with a 30 pack-year history of smoking, presents to the

emergency room with shortness of breath. Chest radiograph demonstrates

a right upper lobe opacity. Computed tomography scan reveals a 3.5-cm

spiculated mass in the peripheral right upper lobe, which is suspicious for

malignancy, without any hilar or mediastinal lymphadenopathy. What is

the next best step in management?

A. Bronchoscopy and biopsy of the mass

B. CT-guided biopsy of the mass

C. Brain MRI

D. Refer to thoracic surgeon for resection.

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 74 (Molecular Biology of

Lung Cancer), 75 (Non–Small Cell Lung Cancer), and 76 (Small Cell and Neuroendocrine Tumors of the Lung).

205